Nebenwirkungen · Adtralza
Adtralza 150 mg solution for injection in pre-filled syringe Adtralza 300 mg solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 6
HOS-145545 · Präparat HOS-099366
The long-term safety of tralokinumab was assessed in 2 monotherapy studies up to 52 weeks, and in a combination study with topical corticosteroids up to 32 weeks. The long-term safety of tralokinumab is further assessed in an open-label extension study (ECZTEND) for up to 5 years of treatment in adults and up to 2 years in adolescents 12 years and older with moderate-to-severe AD (atopic dermatitis) receiving 300 mg of tralokinumab every two weeks (Q2W). The long-term safety data were generally consistent with the safety profile observed up to week 16 in the pool of 5 adult studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-28T11:56:00Z · SHA-256 83eaa444d96a4d6e69d81213cba4604bd7b5b4375717ab35b9ffffc1dd714534 · Passage 2895d51ce692f6611dd9b2de4cee8aec2af5a87f176136cf28491398aac21282 · Zeichen 1451–2040 im Abschnitt